natgillin/translations-raw huggingface dataset:
Epoetin alfa HEXAL 9,000 IU/0.9 ml solution for injection in a pre-filled syringe Each syringe contains 0.9 ml of solution for injection.
Epoetin alfa HEXAL 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,9 ml raztopine za injiciranje.
Epoetin alfa HEXAL 9,000 IU/0.9 ml solution for injection in a pre-filled syringe Epoetin alfa
Epoetin alfa HEXAL 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Epoetin alfa
Epoetin alfa HEXAL 9,000 IU/0.9 ml solution for injection in a pre-filled syringe EU/1/07/411/019
Epoetin alfa HEXAL 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/411/019
Epoetin alfa HEXAL and other products that stimulate red cell production may increase the risk of developing blood clots in all patients.
Zdravilo Epoetin alfa HEXAL in druga zdravila, ki spodbujajo nastajanje rdečih krvnih celic, lahko povečajo tveganje za nastanek krvnih strdkov pri vseh bolnikih.
Epoetin alfa HEXAL contains less than 1 mmol sodium (23 mg) per dose i.e. essentially “sodium free”.
Zdravilo Epoetin alfa HEXAL vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni „brez natrija“.
Epoetin alfa HEXAL does not normally react with other medicines but please tell your doctor if you are using, have recently used or might use any other medicines, including medicines obtained without a prescription.
Zdravilo Epoetin alfa HEXAL običajno ne reagira z drugimi zdravili, vendar obvestite svojega zdravnika, če uporabljate (ali ste pred kratkim uporabljali) katero koli zdravilo, tudi če ste ga dobili brez recepta.
Epoetin alfa HEXAL has no or negligible influence on the ability to drive and use machines.
Zdravilo Epoetin alfa HEXAL nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Epoetin Alfa Hexal is a solution for injection.
Zdravilo Epoetin Alfa Hexal je raztopina za injiciranje.
Epoetin Alfa Hexal is a ‘biosimilar’ medicine.
Zdravilo Epoetin Alfa Hexal je podobno biološko zdravilo.
Epoetin Alfa Hexal is given as an injection into a vein or as an injection under the skin, depending on the condition for which the patient is being treated.
Zdravilo Epoetin Alfa Hexal se daje z injiciranjem v veno ali podkožje, odvisno od bolezenskega stanja bolnika, ki se zdravi.
Epoetin alfa HEXAL is given by injection into a vein immediately after you have donated blood for 3 weeks before your surgery.
Zdravilo Epoetin alfa HEXAL se injicira v veno takoj po tem, ko darujete kri, 3 tedne pred kirurškim posegom.
Epoetin alfa HEXAL is given by injection under the skin each week for three weeks before surgery and on the day of surgery.
Zdravilo Epoetin alfa HEXAL se injicira pod kožo vsak teden tri tedne pred kirurškim posegom in na dan kirurškega posega.
Epoetin alfa HEXAL is given by injection under the skin.
Zdravilo Epoetin alfa HEXAL se daje v obliki injekcije pod kožo.
Epoetin alfa HEXAL is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.
Zdravilo Epoetin alfa HEXAL je indicirano za zdravljenje odraslih, pri katerih s kemoterapijo zdravimo solidne tumorje, maligni limfom ali multipli mielom, in pri tveganju za transfuzijo, ki ga ocenimo glede na bolnikovo splošno zdravstveno stanje (npr. kardiovaskularni status, prisotnost anemije že na začetku zdravljenja s kemoterapijo) za zdravljenje anemije in zmanjšanje potrebe po transfuziji.
Epoetin Alfa Hexal is used for the following:
Zdravilo Epoetin Alfa Hexal se uporablja v naslednjih primerih:
Epoetin alfa HEXAL is used to treat symptomatic anaemia caused by kidney disease:
Zdravilo Epoetin alfa HEXAL se uporablja za zdravljenje simptomatske anemije, ki jo povzroči bolezen ledvic:
Epoetin alfa HEXAL may not be suitable for you.
ne morete jemati zdravil za redčenje krvi zdravilo Epoetin alfa HEXAL morda za vas ni primerno.
Epoetin Alfa Hexal must not be used in the following groups:
Zdravilo se ne sme uporabljati pri naslednjih skupinah bolnikov:
Epoetin alfa HEXAL should be administered by the intravenous route.
Zdravilo Epoetin alfa HEXAL je treba dati intravensko.
Epoetin alfa HEXAL should be administered in order to increase haemoglobin to not greater than 11 g/dl (6.8 mmol/l).
Zdravilo Epoetin alfa HEXAL se daje z namenom zvišati hemoglobin na raven do 11 g/dl (6,8 mmol/l).
Epoetin alfa HEXAL should be administered in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l).
Zdravilo Epoetin alfa HEXAL se daje z namenom zvišati hemoglobin na raven do 12 g/dl (7,5 mmol/l).
Epoetin alfa HEXAL should not be used and discarded
Zdravila Epoetin alfa HEXAL se ne sme uporabiti in ga je treba zavreči:
Epoetin alfa HEXAL should not be used:
Zdravila Epoetin alfa HEXAL ne uporabljajte:
Epoetin Alfa Hexal was as effective as Eprex/Erypo in increasing and maintaining red blood cell counts.
Zdravilo Epoetin Alfa Hexal je bilo pri zviševanju in vzdrževanju števila rdečih krvnih celic enako učinkovito kot zdravilo Eprex/Erypo.
Epoetin Alfa Hexal was studied to show that it is comparable to the reference medicine, Eprex/Erypo.
Zdravilo Epoetin Alfa Hexal so proučevali, da bi dokazali, ali je primerljivo z referenčnim zdravilom Eprex/Erypo.
Epoetin alfa was administered at 75 IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75 IU/kg/week at intervals of 4 weeks (up to a maximum of 300 IU/kg/week), to achieve a 1 g/dl/month increase in haemoglobin.
Epoetin alfa so dajali v odmerku 75 i.e./kg/teden intravensko, v 2 ali 3 razdeljenih odmerkih po dializi, ki so ga v 4-tedenskih intervalih titrirali po 75 i.e./kg/teden (do največ 300 i.e./kg/teden), za dosego povečanja hemoglobina za 1 g/dl/mesec.
Epoetin beta, the active substance of NeoRecormon is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin beta, zdravilno učinkovino zdravila NeoRecormon, sestavljajo iste aminokisline in ogljikovi hidrati kot eritropoetin, ki je bil izoliran iz urina anemičnih bolnikov.
Epoetin beta, the active substance of NeoRecormon, is identical in its amino acid and carbohydrate composition to erythropoietin that has been isolated from the urine of anaemic patients.
Epoetin beta, zdravilno učinkovino zdravila NeoRecormon, sestavljajo iste aminokisline in ogljikovi hidrati kot eritropoetin, ki je bil izoliran iz urina anemičnih bolnikov.
Epoetin delta is produced in human cells (HT-1080) by gene-activation technology.
Epoetin delta je pridobljen iz človeških celic (HT-1080) s posebnim tehnološkim postopkom - gensko aktivacijo.
Epoetin delta, the active ingredient of Dynepo, is a copy of the human hormone, produced by a method known as ‘genetic engineering’: the enzyme is made by a cell in which the gene (the code) for the enzyme is activated so that the cell makes more of the enzyme and it can then be extracted and used in Dynepo.
Zdravilna učinkovina zdravila Dynepo, epoetin delta, ki je kopija človeškega encima, je izdelana po metodi ‘‘genskega inženiringa’’: encim izdela celica, v kateri se aktivira gen (koda) za encim, zaradi česar celica tvori več encima, ki se nato izloči iz nje in uporabi pri izdelavi zdravila Dynepo.
Epoetin theta has no or negligible influence on the ability to drive and use machines.
Epoetin theta nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Epoetin zeta is a copy of the human protein erythropoietin and acts in the same way.
Epoetin zeta je enak beljakovini eritropoetin v človeškem telesu in deluje na enak način.
Epoprostenol: limited data obtained from a study (AC-052-356 [BREATHE-3]) in which 10 paediatric patients received the combination of bosentan and epoprostenol indicate that after both single- and multiple-dose administration, the Cmax and AUC values of bosentan were similar in patients with or without continuous infusion of epoprostenol (see section 5.1).
Epoprostenol: omejeni podatki, pridobljeni v študiji (AC-052-356 [BREATHE-3]), v kateri je 10 pediatričnih bolnikov prejemalo kombinacijo bosentana in epoprostenola, kažejo, da sta bili, tako po enkratnem kot tudi po večkratnem odmerjanju, vrednosti Cmax in AUC za bosentan podobni pri bolnikih s kontinuirano infuzijo epoprostenola ali brez nje (glejte poglavje 5.1).
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 1000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 1,000 IU/0.5 ml, Eporatio 2,000 IU/0.5 ml, Eporatio 3,000 IU/0.5 ml, Eporatio
Eporatio 1000 i.e./0,5 ml, Eporatio 2000 i.e./0,5 ml, Eporatio 3000 i.e./0,5 ml, Eporatio
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 2,000 IU/0.5 ml
Eporatio 2000 i.e./0,5 ml
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 2000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 20.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe EU/1/09/573/017
Eporatio 20.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 3000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 30.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 4000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 5000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eporatio contains the active substance epoetin theta, which is almost identical to erythropoietin, a natural hormone produced by your body.
Zdravilo Eporatio vsebuje zdravilno učinkovino epoetin theta, ki je skoraj enaka eritropoetinu, naravnemu hormonu, ki ga proizvaja telo.
Eporatio therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Eporatio, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Eporatio was effective at treating anaemia in patients with chronic renal failure and patients with non- myeloid cancer who were receiving chemotherapy.
Zdravilo Eporatio je bilo učinkovito za zdravljenje anemije pri bolnikih s kronično ledvično odpovedjo in pri bolnikih z nemielodnim rakom, ki so prejemali kemoterapijo.
EPP patients with fair skin may be more likely to request treatment and are more prone to developing UV light-associated skin changes, including cancer;
Pri bolnikih z EPP, ki imajo svetlo polt, je verjetneje, da bo pri njih potrebno zdravljenje in da so bolj nagnjeni k razvoju z UV-žarki povezanih kožnih sprememb, vključno z rakom;
Eprinomectin interferes with channels in the nerve and muscle cells of roundworms that allow charged chloride particles (ions) to pass, leading to their paralysis and death.
Eprinomektin zavira kanalčke v živčnih in mišičnih celicah glist, kar prepreči prehod nabitih kloridnih delcev (ionov) in povzroči paralizo ter smrt.
epsis (serious infection which can result in organ failure, shock or death)
epsa (huda okužba, ki ima lahko za posledico odpoved organov, šok ali smrt)
epsis* (including bacterial, viral and fungal), neutropenic sepsis*, respiratory tract infection (includes upper and bronchitis), urinary tract infection, cellulitis, diverticulitis, oral fungal infection, sinusitis, pharyngitis, rhinitis, herpes simplex, skin infection
epsa* (vključno z bakterijsko, virusno in glivično), nevtropenična sepsa*, okužbe dihalnih poti (vključujejo zgornja dihala in bronhitis), okužba sečil, celulitis, divertikulitis, glivična okužba ust, sinuzitis, faringitis, rinitis, herpes simpleks, okužba kože
epsis, septic shock, infection of the meninges (meningococcal meningitis), infection of the lung (pneumonia), stomach flu (gastrointestinal infection), cystitis,, lower respiratory tract infection
epsa, septični šok, okužba možganskih ovojnic (meningokokni meningitis), okužba pljuč (pljučnica), trebušna gripa (okužba prebavil), cistitis, okužba spodnjih dihal,
Epstein-Barr Virus-associated lymphoproliferative disorders
Limfoproliferativne bolezni, povezane z virusom Epstein-Barr
Epstein-Barr Virus-associated lymphoproliferative disorders have been observed outside company-sponsored studies.
Izven študij, ki jih je podprl izdelovalec, so ugotovili limfoproliferativne bolezni, povezane z virusom Epstein-Barr.
eptacog alfa (activated)
aktivirani eptakog alfa
Eptacog alfa is not extracted from human blood but is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce eptacog alfa.
Eptakog alfa se ne pridobiva iz človeške krvi, temveč se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celice prejmejo gen (DNK), s katerim lahko tvorijo eptakog alfa.
Eptacog alfa works in the same way as factor VII.
Eptakog alfa deluje na enak način kot faktor VII.
eptic inflammation of a vein with blood clotting (septic thrombophlebitis) or blocked blood vessels at an infected site
eptično vnetje vene s strjevanjem krvi (septični tromboflebitis) ali zamašene krvne žile na okuženem mestu,
eptic shock*
eptični šok
eptic thrombophlebitis or occluded arteriovenous cannula at seriously infected site
eptični tromboflebitis ali zamašena arteriovenska kanila na resno okuženem mestu,
Eptifibatide Accord 0.75 mg/ml solution for infusion
Eptifibatide Accord 0,75 mg/ml raztopina za injiciranje
Eptifibatide Accord 0.75 mg/ml solution for infusion contains 77.4 mg (3.37 mmol) of sodium per maximum daily dose.
Eptifibatide Accord 0,75 mg/ml raztopina za infundiranje vsebuje 77,4 mg (3,37 mmol) natrija na največji dnevni odmerek.
Eptifibatide Accord inhibits platelet aggregation, but does not appear to affect the viability of platelets.
Zdravilo Eptifibatide Accord zavira agregacijo trombocitov, ni pa videti, da bi vplival na njihovo življenjsko dobo.
Eptifibatide Accord is a ‘generic medicine’.
Zdravilo Eptifibatide Accord je „generično zdravilo“.
Eptifibatide Accord is chemically and physically compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride up to 92 hours when stored at 20-25°C. Please refer to the Normosol R Summary of Product Characteristics for details on its composition.
Zdravilo Eptifibatide Accord je kemijsko in fizikalno združljivo z 0,9 % raztopino natrijevega klorida za infundiranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida, do 92 ur pri shranjevanju pri temperaturi 20 °C - 25 °C. Prosimo, glejte Povzetek glavnih značilnosti zdravila Normosol R za podrobnosti o njegovi sestavi.
Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.
Zdravilo Eptifibatide Accord je indicirano za preprečevanje zgodnjega miokardnega infarkta pri odraslih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v elektrokardiogramu (EKG), ki so imeli zadnji napad bolečine v prsih v preteklih 24 urah ter imajo EKG spremembe, zvišano koncentracijo srčnih encimov ali oboje.
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.
Zdravilo Eptifibatide Accord je namenjeno uporabi z acetilsalicilno kilsino in nefrakcioniranim heparinom.
Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age.
Zdravilo Eptifibatide Accord ni namenjeno za uporabo pri otrocih in mladostnikih do 18. leta starosti.
Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units.
Zdravilo Eptifibatide Accord priporočamo za uporabo le pri odraslih bolnikih, hospitaliziranih na bolnišničnih koronarnih oddelkih.
Eptifibatide Accord must not be used to treat patients with:
Z zdravilom Eptifibatide Accord ne smete zdraviti bolnikov z/s:
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors.
Eptifibatid reverzibilno zavira agregacijo trombocitov, saj preprečuje vezavo fibrinogena, von Willebrandovega faktorja in drugih adhezivnih ligandov na receptorje glikoproteina (GP) IIb/IIIa.
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP)IIb/IIIa receptors.
Eptifibatid reverzibilno zavira agregacijo trombocitov, saj preprečuje vezavo fibrinogena, von Willebrandovega faktorja in drugih adhezivnih ligandov na receptorje glikoproteina (GP) IIb/IIIa.
Eptotermin alfa is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce eptotermin alfa.
Eptotermin alfa se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“: proizvajajo ga celice, ki so prejele gen (DNK), zaradi katerega lahko tvorijo eptotermin alfa.
Eptotermin alfa is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce it.
Eptotermin alfa je izdelan z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori eptotermin alfa.
eptum pellucidum agenesis; olfactory nerve agenesis.
agenezija septuma pelluciduma, agenezija olfaktornega živca.
Epworth Sleepiness Scale (ESS; range 0-24)
Epworthova lestvica zaspanosti (ESS; območje 0-24)
Equal amounts of prednisolone, prednisone, 20β- dihydroprednisolone and 20β-dihydroprednisone are found in urine.
V urinu so prisotne enake količine prednizolona, prednizona, 20β- dihidroprednizolona in 20β-dihidroprednizona.
Equidae
Ekvidi
Equilibrate the refrigerated vial of Noxafil to room temperature.
Pustite, da se ohlajena viala z zdravilom Noxafil ogreje na sobno temperaturo.
Equilibrate the vial to room temperature (at or below 25°C).
Pustite, da se viala ogreje na sobno temperaturo (25 °C ali manj).
Equilis Prequenza [a clear pictogram of a horse]
Equilis Prequenza (jasen piktogam konja)
Equilis Prequenza suspension for injection for horses
Equilis Prequenza, suspenzija za injiciranje za konje
Equilis Prequenza Te [a clear pictogram of a horse]
Equilis Prequenza Te (jasen piktogam konja)
Equilis Prequenza Te suspension for injection for horses
Equilis Prequenza Te, suspenzija za injiciranje za konje
Equilis Prequenza, suspension for injection, for horses
Equilis Prequenza, suspenzija za injiciranje, za konje
EQUILIS StrepE EPAR summary for the public
EQUILIS StrepE Povzetek EPAR za javnost
Equilis StrepE – solvent
Equilis StrepE - vehikel
Equilis StrepE, lyophilisate and solvent for suspension for injection
Equilis StrepE, liofilizat za suspenzijo za injiciranje, za konje
Equilis StrepE, lyophilisate and solvent for suspension for injection, for horses
Equilis StrepE, liofilizat in vehikel za suspenzijo za injiciranje, za konje
Equilis StrepE, lyophilisate for suspension for injection, for horses
Equilis StrepE, liofilizat za suspenzijo za injiciranje, za konje
Equilis Te [a clear pictogram of a horse]
Equilis Te [jasen piktogram konja]
Equilis Te suspension for injection for horses
Equilis Te, suspenzija za injiciranje za konje
Equilis West Nile [a clear pictogram of a horse]
Equilis West Nile [piktogram konja]
Equilis West Nile suspension for injection
Equilis West Nile suspenzija za injiciranje
Equilis West Nile suspension for injection for horses
Equilis West Nile suspenzija za injiciranje za konje
Equine influenza and tetanus vaccine
cepivo proti influenci konj in tetanusu
Equine influenza virus strains:
Sevi virusa influence konj
Equine influenza virus strains:
Soji virusa influence konj:
EQUIOXX 20 mg/ml solution for injection Firocoxib
EQUIOXX 20 mg/ml raztopina za injiciranje Firokoksib
EQUIOXX 20 mg/ml solution for injection for horses
EQUIOXX 20 mg/ml raztopina za injiciranje za konje
EQUIOXX 20 mg/ml solution for injection for horses Firocoxib
EQUIOXX 20 mg/ml raztopina za injiciranje za konje Firokoksib
EQUIOXX 8.2 mg/g oral paste for horses
EQUIOXX 8.2 mg/g peroralna pasta za konje
EQUIOXX 8.2 mg/g oral paste for horses Firocoxib
EQUIOXX 8.2 mg/g peroralna pasta za konje Firokoksib
EQUIOXX 8.2 mg/g oral paste for horses.
EQUIOXX 8.2 mg/g peroralna pasta za konje
EQUIOXX contains the active substance firocoxib in an oral paste for horses (8.2 mg/g).
Zdravilo EQUIOXX vsebuje zdravilno učinkovino firokoksib v peroralni pasti za konje (8,2 mg/g).
EQUIOXX has been studied in laboratory animals, as well as in horses that were treated in various veterinary practices/clinics across Europe (“clinical studies”).
Zdravilo EQUIOXX so raziskovali pri laboratorijskih živalih, kot tudi pri konjih, ki so jih zdravili v različnih veterinarskih ambulantah in klinikah po vsej Evropi (klinične študije).
EQUIOXX is presented as a paste with a special syringe that allows the right amount of medicine to be drawn and given directly into the horse’s mouth.
Zdravilo EQUIOXX je v obliki paste na voljo skupaj s posebno brizgo, s pomočjo katere se odmeri in konju neposredno v gobec vbrizga ravno prava količina zdravila.
EQUIOXX is used to relieve the symptoms of osteoarthritis (swelling and pain in the joints) and reduce the lameness that is associated with the disease in horses.
Zdravilo EQUIOXX se uporablja za lajšanje simptomov osteoartritisa (otekanje in bolečine v sklepih) in za zmanjšanje sočasnega šepanja pri konjih.
EQUIOXX must not be administered with corticosteroids or other NSAIDs.
Zdravilo EQUIOXX se ne sme dajati skupaj s kortikosteroidi ali drugimi nesteroidnimi protivnetnimi zdravili (NSAID).
EQUIOXX oral paste administered once daily for 14 days at a dose of 0.1 mg/kg improved clinical scores for lameness and soft tissue injuries in horses and also helped relieve pain and inflammation associated with osteoarthritis in horses.
Zdravilo EQUIOXX v obliki peroralne paste enkrat dnevno v času 14 dni in pri odmerku 0,1 mg/kg je pri konjih izboljšalo klinične ocene šepavosti in poškodb mehkih tkiv ter pomagalo lajšati bolečine in vnetja, povezana z osteoartritisom.
Equip WNV emulsion for injection for horses
Equip WNV emulzija za injiciranje za konje
Equip WNV emulsion for injection for horses
Equip WNV – emulzija za injiciranje za konje
Equip WNV injection for horses
Equip WNV injekcija za konje
Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats.
Pri zaporedni uporabi deksmedetomidina in ketamina za anestezije pri mačkah lahko pride do dihalnega zastoja ali prenehanja dihanja, zato imejte pri roki opremo za ročno ventilacijo.
Equipment required for administration
Oprema, ki je potrebna za injiciranje
Equipment that you need
Kaj vse potebujete
Equisolon 100 mg oral powder for horses Equisolon 300 mg oral powder for horses Equisolon 600 mg oral powder for horses Prednisolone
Equisolon 100 mg peroralni prašek za konje Equisolon 300 mg peroralni prašek za konje Equisolon 600 mg peroralni prašek za konje prednizolon
Equisolon 33 mg/g oral powder for horses prednisolone
Equisolon 33 mg/g peroralni prašek za konje prednizolon